+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Scaling problems in parkinsons disease



Scaling problems in parkinsons disease



Requin, J And G E Stelmach Nato Asi (Advanced Science Institute) Series Series D Behavioural And Social Sciences, Vol 62 Tutorials in Motor Neuroscience; Symposium on Motor Neuroscience, Calcatoggio, Corsica, France, September 15-24, 1990 Xx+672p Kluwer Academic Publishers: Dordrecht, Netherlands; Norwell, Massachusetts, Usa Illus 161-174




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 033299146

Download citation: RISBibTeXText


Related references

Comparison of the Unified Parkinsons Disease Rating Scale and Short Parkinsons Evaluation Scale after Levodopa loading test in Parkinsons disease. Neurology 56(8 Suppl. 3): A282, 2001

Problems in parkinsons disease. Marsden, C D And S Fahn (Ed ) Butterworths International Medical Reviews Neurology, Vol 2 Movement Disorders Xiii+379p Butterworth, Inc : London, England; Boston, Mass , Usa Illus P1-7, 1982

Discretely scaling a continuous movement Parkinsons Disease patients have more variable movement trajectories. Society for Neuroscience Abstracts 27(2): 2209, 2001

Patterns of neuropsychological impairment are distinct in parkinsons disease alzheimers disease and parkinsons disease dementia. Neurology 41(3 Suppl. 1): 177, 1991

The Nonmotor Problems Of ParkinsonS Disease. The Neurologist 6(1): 18-27, 2000

Biochemical and pharmacological problems of parkinsons disease. Medico (Porto) 60(1045): 442-445, 1971

Problems of l dopa therapy in the course of parkinsons disease. Fortschritte der Neurologie Psychiatrie 57(5): 192-197, 1989

Sleep problems in Parkinsons disease patients. Neurodegenerative Disease Management 1(4): 307-321, 2011

A radical basis of nigrostriatal dopamine cell death in Parkinsons disease Oxygen free radicals and Parkinsons disease. Racagni, G , Brunello, N , Langer, S Z International Academy for Biomedical and Drug Research; Recent advances in the treatment of neurodegenerative disorders and cognitive dysfunction 229-237, 1994

Self-reported functioning and well-being in patients with Parkinsons disease Comparison of the short-form health survey and the Parkinsons disease questionnaire. Age & Ageing 24(6): 505-509, 1995

Possibilities for optimizing treatment of Parkinsons disease Ninth international symposium on Parkinsons disease, June 5-9, 1988 in Jerusalem. Zhurnal Nevropatologii i Psikhiatrii Imeni S S Korsakova 92(2): 136-137, 1992

Determination of minimal important difference thresholds for Parkinsons disease questionnaire-39 in advanced Parkinsons disease patients. Parkinsonism & Related Disorders 22: E95-E96, 2016

Etiology of parkinsons disease complex i deficiency in 1 methyl 4 phenyl 1 2 3 6 tetrahydropyridine induced parkinsonism and parkinsons disease. Sato, T And S Dimauro Progress in Neuropathology, Vol 7 Mitochondrial Encephalomyopathies; Satellite Symposium Of The Xith International Congress Of Neuropathology, Tokyo, Japan, August 31-September 1, 1990 Xxi+258p Raven Press: New York, New York, Usa Illus 237-247, 1991

Determination of minimal important difference thresholds for Parkinsons disease Questionnaire-39 in advanced Parkinsons disease patients. Parkinsonism & Related Disorders 22: E18-E19, 2016

Enhanced binding to NMDA receptors in the striatum of Parkinsons disease, Alzheimers disease and mixed Parkinsons disease/Alzheimers disease patients. Society for Neuroscience Abstracts 19(1-3): 194, 1993